What lands in your inbox when you join The Stack.
Doses, brands, day counts — with the blood work next to the anecdote. This isn’t for everyone.
The Stack.
Get the next letter and your Catalyst access.
What’s inside
Three things, every Monday. No filler.
- 01
The stack of the week.
What I’m running. Dose, brand, day count, why.
- 02
Vetted sources.
Who I trust, who I dropped, who the community verified.
- 03
One N=1 protocol.
Blood work, body comp, the dose I bumped, the dose I cut.
I cut my GLP-1 dose in half. The fat loss didn't stop.
Day 84 of the 12-week Retatrutide protocol. Down 22 lbs. Held muscle.
Here's what nobody tells you about the second month on a GLP-1: the food noise comes BACK. Not as loud, but back.
What I did: bumped the dose from 6mg to 8mg for two weeks. Bad call. Lost an extra pound of muscle. Bad trade.
So I dropped it back. To 4mg. And here's what happened. The fat loss didn't stop. It accelerated. Because — and this is the part most people miss — what was driving the fat loss wasn't the dose anymore. It was the meal pattern I'd built around the dose.
Stack No. 01 — Welcome. Doses. Brands. Day counts.
What’s next in the Stack
Six weeks. Six letters. Subscribe before #14 drops.
- Issue 14 · This MondaySun Jul 27
BPC-157 oral — Day 21 results.
→ Next drop - Issue 15 · +1 weekSun Aug 3
GLP-1 stack: the support cast nobody runs.
- Issue 16 · +2 weeksSun Aug 10
Source verification report — 4 vendors tested.
- Issue 17 · +3 weeksSun Aug 17
TB-500: when it's the right call, when it isn't.
- Issue 18 · +4 weeksSun Aug 24
NAD+ — IV vs oral vs subq. What I actually run.
- Issue 19 · +5 weeksSun Aug 31
Vacation hacks — Q3 travel damage mitigation.
Tentative · order may change based on N=1 surprises
BPC-157, quietly rewriting recovery.
If you’ve ever pulled a tendon or blown out a shoulder — this letter is going to change the game for you. BPC-157BPC-157 · mechanismPentadecapeptide. Tendon, gut, recovery. The repair signal., 250 mcg twice daily, subq, sixty days. By day twenty-one the ache was gone. By day forty I was back under the bar. Straight fresh from the N=1.
The peer-reviewed work on the mechanism is solid. The human clinical evidence is still thin — the molecule can’t be patented, so nobody funded the big trial. What you’re left with is what the community has actually run. That’s what The Stack is for.
Start low, go slow. BPC-157 is the star player — TB-500TB-500 · mechanismThymosin Beta-4 fragment. Soft-tissue + recovery. Pairs with BPC-157. is the support, KPV the role player. In the full letter: the stack, the reconstitution math, the two sources I trust this quarter.
Free · full archive after subscribe
— By Barry · 2026
·oe·